Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | HTR2B | P41595 | 3/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | HTR1D | P28221 | 2/20 | 0.44 |
| ▸ | HTR1E | P28566 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9309358 | 0.81 | HTR2A (0.56) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| SCHEMBL3337970 | 0.80 | HTR2A (0.67) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| SCHEMBL2465013 | 0.79 | SLC6A2 (0.57) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| SCHEMBL28189260 | 0.78 | GPR84 (0.69) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| SCHEMBL29611508 | 0.78 | GPR84 (0.51) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| SCHEMBL9060404 | 0.78 | GPR84 (0.51) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| SCHEMBL10870620 | 0.78 | GPR84 (0.69) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| Hydrochloric Acid SCHEMBL21546033 | 0.77 | GPR84 (0.67) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| SCHEMBL6888701 | 0.75 | GPR84 (0.56) | HTR2AHTR2CHTR2BGPR84FFAR1 | |
| SCHEMBL28271504 | 0.75 | GPR84 (0.71) | HTR2AHTR2CHTR2BGPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| US-8383859-B2 | Methods of preparing primary, secondary and tertiary carbinamine compounds in the presence of ammonia | THADANI AVINASH N (CA) | 2013-02-26 | — | — | US | disclosed |
| US-8350047-B2 | Methods of preparing secondary carbinamine compounds with boronic acids | THADANI AVINASH N (CA) | 2013-01-08 | — | — | US | disclosed |
| US-8350047-B2 | Methods of preparing secondary carbinamine compounds with boronic acids | THADANI AVINASH N (CA) | 2013-01-08 | — | — | US | disclosed |
| US-8350047-B2 | Methods of preparing secondary carbinamine compounds with boronic acids | THADANI AVINASH N (CA) | 2013-01-08 | — | — | US | disclosed |
| US-20100298572-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | PANASONIC CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100298572-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | PANASONIC CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100298572-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | PANASONIC CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100174090-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | THADANI AVINASH N | 2010-07-08 | — | — | US | disclosed |
| US-20100174090-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | THADANI AVINASH N | 2010-07-08 | — | — | US | disclosed |
| US-20100174090-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | THADANI AVINASH N | 2010-07-08 | — | — | US | disclosed |
| WO-2008119162-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119161-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119162-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119161-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174090-A1 | METHODS OF PREPARING PRIMARY, SECONDARY AND TERTIARY CARBINAMINE COMPOUNDS IN THE PRESENCE OF AMMONIA | HNMT, AADAT, DAO | HTR2A 1380/4885HTR2C 1558/4885HTR2B 1596/4885 |
| US-20100298572-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | C9, BCAT2, SLC1A5 | HTR2A 2991/4885HTR2C 3503/4885HTR2B 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.